Cancer Surgery — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Cancer surgery is the surgical removal or destruction of tumour tissue to cure, stage, debulk, or palliate malignant disease. It is the oldest cancer treatment and remains the primary curative modality for most solid tumours. Surgery plays distinct roles across the cancer treatment pathway: curative resection aims for complete tumour removal with clear histological margins (R0 resection); staging procedures establish tumour extent and guide adjuvant treatment decisions; debulking (cytoreductive) surgery reduces tumour burden to enhance chemotherapy efficacy (as in ovarian cancer); and palliative surgery relieves symptoms — obstruction, bleeding, or pain — without attempting cure in advanced disease. Cancer surgery is almost always performed under general anaesthesia and is increasingly delivered using minimally invasive approaches — laparoscopic, thoracoscopic, or robotic — which offer reduced blood loss, shorter hospital stay, and faster recovery while maintaining equivalent oncological outcomes to open surgery for most tumour types. The principle of surgery within a multidisciplinary team (MDT) ensures that the optimal sequence of treatments — surgery alone, neoadjuvant therapy before surgery, or adjuvant therapy after — is planned for every patient. Cancer surgery is the surgical removal or destruction of tumour tissue to cure, stage, debulk, or palliate malignant disease. It is the oldest cancer treatment and remains the primary curative modality for most solid tumours. Surgery plays distinct roles across the cancer treatment pathway: curative (with negative surgical margins removing all detectable tumour), debulking (reducing tumour burden to improve chemoradiotherapy efficacy), staging (sampling lymph nodes or biopsy to guide treatment decisions), and palliative (relieving obstruction, pain, or bleeding). More than 60% of cancer patients require surgery at some point during their care. Surgical oncology is the surgical specialty dedicated to cancer operations and is practised by surgeons with additional training in oncological principles including wide resection margins, lymphadenectomy, reconstruction, and multidisciplinary tumour board decision-making. Minimally invasive techniques (laparoscopic, robotic) are increasingly adopted for colorectal, gynaecological, and urological cancers.

Surgery is indicated as the primary treatment for resectable solid tumours of the breast, colon, rectum, lung, prostate, kidney, thyroid, skin (melanoma, SCC, BCC), uterus, cervix, ovary, stomach, oesophagus, liver, and pancreas. 'Resectability' depends on absence of local invasion into major vessels or structures, absence of distant metastases (or oligometastatic disease amenable to combined resection), and patient fitness for anaesthesia and surgery. Patient selection involves CT/MRI/PET-CT staging, performance status assessment, and MDT discussion. Surgery is the preferred treatment for localised or regionally contained disease. When tumours are initially unresectable due to size or vascular proximity, neoadjuvant chemotherapy or chemoradiotherapy may downstage the tumour to enable curative resection — a strategy used in rectal cancer, oesophageal cancer, breast cancer, and borderline-resectable pancreatic cancer. Emergency cancer surgery is performed for complications — bowel obstruction, perforation, or haemorrhage — regardless of disease stage. Patients with germline mutations (BRCA1/2, Lynch syndrome) may undergo prophylactic surgery to prevent primary cancer.

Cancer surgery is highly variable depending on tumour type, location, and extent, but universal surgical oncology principles apply to all operations. Adequate surgical margin: the tumour is excised with a margin of normal surrounding tissue — margin width varies by tumour type (1 mm for colorectal cancer, 1 cm for melanoma, 2 cm for SCC). Wide local excision preserves the organ (breast-conserving surgery, nephron-sparing nephrectomy). Radical resection removes the entire organ when preserving it risks inadequate margins (total mastectomy, colectomy, pneumonectomy, cystectomy). Lymph node assessment: regional lymph nodes are assessed for metastasis either by sentinel lymph node biopsy (breast, melanoma, vulvar, endometrial) — where the first draining node is identified and biopsied to spare full lymph node dissection if negative — or by formal lymph node dissection when nodes are clinically involved. Reconstructive surgery: immediate or delayed reconstruction restores form and function after disfiguring resections (breast reconstruction, jaw reconstruction, colostomy reversal). Minimally invasive approaches are now standard for colorectal cancer (laparoscopic or robotic), lung cancer (VATS), gynaecological cancers, and partial nephrectomy — equivalent oncological outcomes with superior recovery. Cancer surgery is highly variable depending on tumour type, location, and extent, but universal surgical oncology principles apply. Adequate surgical margin: the tumour is excised with a margin of normal surrounding tissue (margin width varies by tumour type). En-bloc resection: adjacent structures that may be infiltrated are removed together with the primary tumour. Lymphadenectomy: regional lymph nodes draining the tumour are sampled (sentinel node biopsy) or systematically removed (formal lymph node dissection) to determine nodal staging and reduce locoregional recurrence risk. Reconstruction: after resection, defects are repaired using primary closure, flap reconstruction, or prosthetic implants. Intraoperative frozen section pathology provides real-time margin analysis to confirm complete tumour removal before wound closure. All resected specimens are sent for definitive histopathological analysis including tumour type, grade, margin status, lymphovascular invasion, and nodal involvement, informing adjuvant treatment planning.

Complete surgical resection with histologically clear margins (R0 resection) is the single most important prognostic factor for solid tumour cure. Five-year survival rates demonstrate the impact: Stage I breast cancer treated with surgery achieves 99% 5-year survival; Stage I colon cancer 90%; Stage I lung cancer 80–90%; Stage I cervical cancer 91%. R0 resection of colorectal liver metastases achieves 5-year survival of 40–50% — a remarkable result for metastatic disease. Neoadjuvant therapy followed by surgery has transformed outcomes in locally advanced rectal cancer (pathological complete response in 20–30%), improving local control and enabling sphincter preservation. Minimally invasive surgery delivers equivalent cancer outcomes with additional patient benefits: laparoscopic colectomy reduces post-operative stay by 1–2 days, blood transfusion requirement, and surgical-site infection rate compared with open surgery. Prophylactic bilateral salpingo-oophorectomy in BRCA1/2 carriers reduces ovarian cancer risk by 95% and breast cancer risk by 50% in premenopausal women.

Cancer surgery risks vary substantially by procedure type, extent, patient comorbidities, and whether surgery follows prior radiotherapy (which impairs wound healing). General surgical risks include bleeding requiring transfusion, wound infection, deep venous thrombosis and pulmonary embolism (DVT/PE — prophylaxis with LMWH and mechanical compression is standard), anastomotic leak (major risk after bowel resection — 2–7% for colorectal anastomoses), and pneumonia. Functional deficits depend on the organ and extent of resection: lung function reduction after pneumonectomy, post-laryngectomy voice loss, bladder dysfunction after radical cystectomy, lymphoedema after axillary or groin lymph node dissection, sexual dysfunction after radical prostatectomy or rectal excision. Adjuvant radiotherapy increases wound healing complications in re-operated fields. Positive surgical margins (R1 resection) require re-excision or adjuvant radiotherapy to reduce local recurrence risk. Risk of disease recurrence is not eliminated by surgery, particularly for high-grade or node-positive tumours, which require adjuvant systemic therapy.

Recovery timelines are procedure-specific. Enhanced Recovery After Surgery (ERAS) protocols, now standard at major cancer centres, reduce post-operative hospital stay by 30–40% through preoperative carbohydrate loading, minimised bowel preparation, multimodal analgesia reducing opioids, early oral feeding, and early mobilisation. Hospital stay ranges from same-day (minor excisions) to 1–2 days (laparoscopic colectomy or nephrectomy), 3–5 days (open abdominal resections), and 7–10 days (pancreatectomy or oesophagectomy). Wound care, drain management, and stoma care education are provided before discharge. Adjuvant chemotherapy or radiotherapy typically begins 4–6 weeks post-operatively once wound healing is confirmed. Oncology follow-up with imaging surveillance is scheduled according to tumour type — typically 3–6 monthly for the first 3 years, then annually. Physiotherapy and occupational therapy support rehabilitation after limb-sparing surgery or major resections. Psychological support for cancer diagnosis and surgical disfigurement or functional loss is an integral component of post-operative care at cancer centres.